These disadvantages make development of a highly efficient, long-term therapeutic for HIV-1 infection that is based on inhibition of CCR5 expression through RNAi very unlikely, while more robust CCR5 targeting approaches can allow for better therapeutic outcomes. Here, CCR5 is linked to HIV-1 infection.